Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Over 150 Biotech Executives Sign Letter Against Trump’s Immigration Ban

XTALKS VITALS NEWS

Document

Their objection to the temporary ban centered on its potential impact on the drug development industry, with the authors stating that the US is currently the world leader in pharmaceutical innovation.

Share this!

February 10, 2017 | by Sarah Hand, M.Sc.

In a letter to the editor of the Nature Biotechnology Trade Secrets blog, 166 biotechnology executives have expressed their concern regarding President Donald Trump’s travel ban on those coming from seven Muslim countries. Their objection to the temporary ban centered on its potential impact on the drug development industry, with the authors stating that the US is currently the world leader in pharmaceutical innovation.

“The United States has led the world in medicine production for decades, not only because of its ability to finance drug discovery, but also because, more than any other country, the United States represents opportunity regardless of borders, gender, race, sexual orientation or political cast,” read the letter. “This has enabled our industry to attract the best talent, wherever it is found. This aspect of our industry is a core reason the United States has built its unique strength in biopharmaceuticals.”



The letter goes on to stress the importance of immigration in all areas of the life sciences, including laboratories, research facilities and businesses. The authors also cite a 2014 study which found that of the 69,000 biomedical researchers in the US that year, 52 percent were born outside the country.

According to the authors, while Trump’s immigration ban only includes seven Muslin majority nations, global employees of biotech and pharmaceutical companies are interpreting the executive order to mean that, “America is no longer welcoming of any immigrants, whatsoever.” Employees from other nations have expressed concerns that the ban could be expanded to their country of origin, and they are delaying travel plans which involved leaving the US for fear that they may not be able to reenter.

“If this misguided policy is not reversed, America is at risk of losing its leadership position in one of its most important sectors, one that will shape the world in the twenty-first century,” continued the letter. “Indeed, it will harm an industry dominated by smaller companies and startups, the very kind of industry the administration has said it wants to support. It will slow the fight against the many diseases that afflict us, as well as carry negative economic consequences for the United States.”

Last week, the United States District Court Western District of Washington at Seattle issued a temporary restraining order against Trump’s travel ban. While the restraining order will prevent the ban from being enforced, the president plans to overturn the ruling. Yesterday, the US Court of Appeals refused to reinstate the travel  ban.


Keywords: Biotech, Pharmaceutical, Trump


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.